Tumour heterogeneity and immune-modulation.
Tumour heterogeneity and immune-modulation.
复制标题
DOI：
10.1016/j.coph.2013.04.006
复制
发表时间：
2013-08
影响因子：
4
通讯作者：
Swanton, Charles
中科院分区：
文献类型：
--
作者：
Jamal-Hanjani, Mariam;Thanopoulou, Eirini;Peggs, Karl S.;Quezada, Sergio A.;Swanton, Charles
肿瘤内异质性（ITH）已在多种肿瘤类型中得到证实。不同的克隆亚群可以存在于肿瘤的不同区域内。 ITH 对癌症诊断和治疗具有明显的影响。越来越多的证据表明 ITH 与耐药性之间存在关联。 ITH 可能允许有效使用针对肿瘤新抗原的免疫疗法。测序技术的最新进展揭示了不同癌症类型的个体肿瘤内以及原发性肿瘤和转移性肿瘤之间广泛的肿瘤内异质性（ITH）。随着越来越多的证据将 ITH 与治疗耐药性联系起来，这种遗传多样性可能对癌症诊断和治疗具有临床意义。尽管如此，在限制靶向药物活性的同时，肿瘤遗传异质性可能通过产生新抗原来提供新的治疗机会，这些新抗原可以被患者自身的免疫系统识别和靶向，以响应免疫调节疗法。需要进行纵向基因组研究来评估肿瘤克隆结构及其与每个特定患者对癌症的潜在免疫反应的相关性，以跟踪肿瘤随时间和治疗的进化动态，以便进一步了解耐药性背后的机制并为新的组合治疗策略的开发提供信息。
Intratumour heterogeneity (ITH) has been demonstrated in various tumour types. Distinct clonal subpopulations can exist within different regions of a tumour. ITH has evident implications for cancer diagnosis and treatment. There is increasing evidence for the association between ITH and drug resistance. ITH may allow the effective use of immunotherapeutics against tumour neo-antigens. Recent advances in sequencing technologies have revealed extensive intratumour heterogeneity (ITH) both within individual tumours and between primary and metastatic tumours for different cancer types. Such genetic diversity may have clinical implications for both cancer diagnosis and treatment with increasing evidence linking ITH and therapeutic resistance. Nonetheless, whilst limiting the activity of targeted agents, tumour genetic heterogeneity may provide a new therapeutic opportunity through generation of neo-antigens that could be recognised and targeted by the patient's own immune system in response to immune-modulatory therapies. Longitudinal genomic studies assessing tumour clonal architecture and its correlation with the underlying immune response to cancer in each particular patient are needed to follow tumour evolutionary dynamics over time and through therapy, in order to further understand the mechanisms behind drug resistance and to inform the development of new combinatorial therapeutic strategies.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
HER2 neu 异质性的临床重要性。
影响因子：
0.8
作者：
Davila, Enrique;Amazon, Kip
通讯作者：
Amazon, Kip
影响因子：
64.8
作者：
Greaves, Mel;Maley, Carlo C.
通讯作者：
Maley, Carlo C.
影响因子：
11.2
作者：
Birkbak NJ;Eklund AC;Li Q;McClelland SE;Endesfelder D;Tan P;Tan IB;Richardson AL;Szallasi Z;Swanton C
通讯作者：
Swanton C
影响因子：
64.8
作者：
通讯作者：
--